PCSK9 pipeline

被引：0
|
作者：
Mullard, Asher
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 12期
关键词：
D O I：
10.1038/nrd.2016.258
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
[No abstract available]
引用
收藏
页码：811 / 811
页数：1
相关论文
共 50 条
  • [41] Clinical aspects of PCSK9
    Cariou, Bertrand
    Le May, Cedric
    Costet, Philippe
    ATHEROSCLEROSIS, 2011, 216 (02) : 258 - 265
  • [42] PCSK9 Association With Lipoprotein(a)
    Tavori, Hagai
    Christian, Devon
    Minnier, Jessica
    Plubell, Deanna
    Shapiro, Michael D.
    Yeang, Calvin
    Giunzioni, Ilaria
    Croyal, Mikael
    Duell, P. Barton
    Lambert, Gilles
    Tsimikas, Sotirios
    Fazio, Sergio
    CIRCULATION RESEARCH, 2016, 119 (01) : 29 - +
  • [43] Update on PCSK9 inhibition
    Katzmann, Julius L.
    Custodis, Florian
    Schirmer, Stephan H.
    Laufs, Ulrich
    HERZ, 2022, 47 (03) : 196 - 203
  • [44] Epigenetic editing of PCSK9
    Le Bras, Alexandra
    LAB ANIMAL, 2025, 54 (04) : 76 - 76
  • [45] The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
    Ataei, Sarina
    Ganjali, Shiva
    Banach, Maciej
    Karimi, Ehsan
    Sahebkar, Amirhossein
    ARCHIVES OF MEDICAL SCIENCE, 2023, 19 (01) : 203 - 208
  • [46] Impact of Baseline PCSK9 Levels on the Efficacy of Evolocumab, a Monoclonal Antibody Against PCSK9
    Desai, Nihar
    Giugliano, Robert
    Wasserman, Scott
    Gibbs, John
    Liu, Thomas
    Scott, Robert
    Sabatine, Marc
    CIRCULATION, 2014, 130
  • [47] High glucose effects on PCSK9 expression in aortic VSMC: role of PCSK9 inhibitors
    Barale, C.
    Melchionda, E.
    Russo, I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S421 - S421
  • [48] PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
    Paciullo, Francesco
    Momi, Stefania
    Gresele, Paolo
    THROMBOSIS AND HAEMOSTASIS, 2019, 119 (03) : 359 - 367
  • [49] PCSK9-Hemmung – ein UpdateUpdate on PCSK9 inhibition
    Julius L. Katzmann
    Florian Custodis
    Stephan H. Schirmer
    Ulrich Laufs
    Herz, 2022, 47 : 196 - 203
  • [50] MEASURING PCSK9 LEVELS PRIOR TO COMMENCEMENT OF TREATMENT TO INVESTIGATE THE VARIED RESPONSE TO PCSK9 THERAPY
    Peers, K.
    Wiggins, H.
    Ramachandran, S.
    Jones, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2019, 38 : E3 - E3
12345